Related Experiment Video
Updated: Feb 21, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Pharmacogenomics and Psychiatric Clinical Care
Journal of Psychosocial Nursing and Mental Health Services
|October 10, 2017
Summary
Pharmacogenetic testing can help personalize mental health treatment by explaining patient variability in medication response. This genetic approach shows promise for improving patient outcomes and reducing healthcare costs.
Area of Science:
- Psychiatry
- Pharmacology
- Genetics
Background:
- Mental health disorders affect a significant portion of the US population, leading to substantial disability.
- Many mental illnesses are chronic, and current treatments often result in suboptimal patient remission rates.
- Patient variability in medication response necessitates personalized treatment strategies.
Purpose of the Study:
- To review the clinical application of pharmacogenetic testing in psychiatric care.
- To explore the relationship between specific gene variants and psychiatric illness treatment.
- To highlight the potential of pharmacogenetics in improving patient outcomes.
Main Methods:
- Review of current literature on pharmacogenetic testing in mental health.
- Analysis of clinical data regarding gene variants and psychiatric medication response.
- Examination of evidence on the impact of genetic testing on patient outcomes and healthcare costs.
Main Results:
- Pharmacogenetic testing is clinically used for a subset of gene variants relevant to psychiatric conditions.
- Evidence suggests genetic testing can improve patient outcomes in psychiatric treatment.
- Implementing genetic testing may lead to decreased healthcare expenditures.
Conclusions:
- Pharmacogenetic testing offers a valuable tool for understanding and addressing patient variability in psychiatric medication response.
- Personalized treatment plans guided by genetic insights can enhance therapeutic efficacy.
- Further integration of pharmacogenetics in psychiatric practice holds potential for improved patient care and cost-effectiveness.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
46
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
46
01:29Pharmacogenomics: Identification of New Drug Targets
29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
24
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24
01:27Pharmacogenetics of Drug Metabolism: Overview
31
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
31
01:27Principles of Pharmacogenetics: Types of Genetic Variants
29
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
29
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
27
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27